Goldline Pharmaceutical IPO

Goldline Pharmaceutical Limited is engaged in the marketing of pharmaceutical products under its proprietary brand "Goldline". The company does not manufacture any products itself but operates through a third-party manufacturing model through contractual arrangements with manufacturers who manufacture products based on Goldline's market research, demand analysis, and specifications. Currently, the company is working with 15 manufacturers and 8 distributors.

Its product portfolio spans across five divisions: 1) Goldline Pharma division consists of 42 products which cater to multi-speciality outpatient needs, including Orthopaedics, ENT, Gastroenterology, Neurology, and Urology. 2) The Goldline Cardinal division includes 54 products, which focus on cardio-diabetic therapies for chronic lifestyle diseases like cardiovascular disorders and diabetes, requiring long-term treatment. 3) The Goldline Aayushman division offers 18 products that target gynaecology and pediatric segments, addressing the healthcare needs of women and children. 4) The Goldline InLife division includes 22 products, including injectables and critical care products mainly used in hospital and ICU settings. 5) The Goldline Wellness division has 10 products that are designed to support and adjunct therapies for cancer patients and survivors, aiming at improving treatment tolerance and quality of life.

Maharashtra is by far the biggest geographic market for the company's revenues, accounting for nearly 44 to 51% of total revenues during FY23 to 9MFY26, while Madhya Pradesh is the second largest market, making up about 26-29%, and the remaining geographic markets of Odisha, Jharkhand, Tamil Nadu, and Rajasthan make up relatively smaller amounts of revenues. Chhattisgarh saw substantial growth from 0.36% of revenue in FY23 to 3.96% in 9MFY26. The top customer contributed around 35 to 40% of total revenues across all periods, and the top 5 customers contributed ~77-79% of revenues. Approximately 99.8% to 100% of the revenues between FY23 and 9MFY26 were generated through wholesaler transactions; there are no significant direct retail sales.